多种药物警戒模型联合应用可提高模拟前瞻性监测的信号检测及时性
该模拟研究评估了在真实暴露-风险关联未知时,同时拟合多种暴露模型并联合证据能否提高前瞻性药物警戒信号检测的及时性。结果显示,联合一组精心选择的参数模型与灵活模型,其检测时间可与依赖单一「真实」模型的理想情景相当,提示多模型策略可在未知真实模型时更及时地检出关联。
要点
- 真实暴露-风险关联未知时,单一暴露模型可能延误信号检测。
- 联合多种假设不同关联形式的模型可缩短模拟中的检测时间。
- 多模型联合的检测及时性接近依赖单一真实模型的理想情景。
核心结论
- 在真实模型未知时,先拟合一组精心选择的暴露-风险模型,任一模型检验统计量低于预设阈值即产生信号,可更及时地检出关联。
研究设计与样本
- 模拟研究:模拟时变药物暴露与不良事件风险之间的多种临床合理关联,并在随访多个时间点估计参数与半参数暴露-风险模型进行前瞻性监测。
主要发现
- 拟合一组包含假设不同暴露-风险关联的参数模型及不对关联形式作假设的灵活模型,可在各模拟关联下实现及时检测。
- 多模型证据简单联合所得的检测时间,与依赖数据生成所用单一「真实」模型的理想情景相当。
临床怎么用
- 真实暴露-风险关联不确定时,可同时拟合一组精心选择的暴露-风险模型并联合证据进行信号检测。
局限性
- 结论基于模拟数据,尚未在真实药物警戒数据中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Prospective pharmacovigilance aims to rapidly detect safety concerns related to medical products. The exposure model selected for pharmacovigilance impacts the timeliness of signal detection. However, in most real-life pharmacovigilance studies, little is known about which model correctly represents the association and there is no evidence to guide the selection of an exposure model. Different exposure models reflect different aspects of exposure history, and their relevance varies across studies. Therefore, one potential solution is to apply several alternative exposure models simultaneously, with each model assuming a different exposure-risk association, and then combine the model results. METHODS: We simulated alternative clinically plausible associations between time-varying drug exposure and the hazard of an adverse event. Prospective surveillance was conducted on the simulated data by estimating parametric and semi-parametric exposure-risk models at multiple times during follow-up. For each model separately, and using combined evidence from different subsets of models, we compared the time to signal detection. RESULTS: Timely detection across the simulated associations was obtained by fitting a set of pharmacovigilance models. This set included alternative parametric models that assumed different exposure-risk associations and flexible models that made no assumptions regarding the form/shape of the association. Times to detection generated using a simple combination of evidence from multiple models were comparable to those observed under the ideal, but unrealistic, scenario where pharmacovigilance relied on the single 'true' model used for data generation. CONCLUSIONS: Simulation results indicate that, if the true model is not known, an association can be detected in a more timely manner by first fitting a carefully selected set of exposure-risk models and then generating a signal as soon as any of the models considered yields a test statistic value below a predetermined testing threshold.
引用
- van Gaalen RD, Abrahamowicz M, Buckeridge DL, et al. Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance. Drug Saf. 2017. PMID: 28664355. doi:10.1007/s40264-017-0555-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。